UTILIZATION OF PHOSPHATIDYLSERINE IN THE TREATMENT OF ATTENTION DEFICIT SYNDROME (ADHS)

摘要

The invention relates to the utilization of phosphatidylserine (PS), lysophosphatidylserine and/or a physiologically acceptable salt thereof in the treatment of attention deficit syndrome (ADHS) in small daily doses over an extended period and in high doses over a short period and in combination with appropriate additives selected from the group consisting of antioxidants, essential fatty acids, mineral substances, amino acids, antidepressants and/or phospholipids. It is preferably administered to probands in the 2 to 20 years age group, preferably in the 3 to 10 years age group, wherein the phosphatidylserine and the additives can be used both in solid or liquid formulations. Phosphatidylserine is particularly suitable as therapeutic agent or diet supplement in connection with ADHS due to its positive properties. The good compatibility of phosphatidylserine even in high doses and over extended supplementation periods and its excellent compliance should also be stressed.